Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
60 Results for "
mPTP
" in MedChemExpress (MCE) Product Catalog:
Products (60)
60 Results for "mPTP" in MCE Product Catalog:
Cat. No.: HY-W683866
CAS No.: 16378-21-5
Target:
Research Areas:
Piroheptine is a muscarinic acetylcholine receptor (mAChR) antagonist and dopamine reuptake inhibitor. Piroheptine blocks the high-affinity dopamine transport system, prevents MPP + uptake into dopaminergic neurons, and exerts anticholinergic activity. Piroheptine completely prevents MPTP (HY-W114750)-induced loss of striatal dopamine and DOPAC, and increases striatal dopamine levels. Piroheptine can be used in studies related to Parkinson's disease .
Cat. No.: HY-P12279
Target:
Keap1-Nrf2 α-synuclein PINK1/Parkin Autophagy Apoptosis Reactive Oxygen Species (ROS) SOD Glutathione Peroxidase Cholinesterase (ChE)
Research Areas:
MAAAHR is a neuroprotective agent. MAAAHR is isolated and purified from C-phycocyanin of Spirulina platensis. MAAAHR induces antioxidant gene expression through activating the Nrf2 signaling pathway. MAAAHR inhibits excessive Autophagy by reducing the expression of proteins such as α-Syn and Parkin. MAAAHR inhibits Apoptosis. MAAAHR scavenges excessive ROS, enhances SOD, CAT, and GSH-Px activities, and reduces protein carbonyl content. MAAAHR inhibits Acetylcholinesterase. MAAAHR protects zebrafish against MPTP (HY-15608)-induced dopaminergic neuronal and neurovascular loss and alleviates motor impairment. MAAAHR can be used for research on Parkinson's disease .
Cat. No.: HY-P12336
Target:
Drug Derivative Cholinesterase (ChE) Reactive Oxygen Species (ROS) Caspase Keap1-Nrf2 PINK1/Parkin Bcl-2 Family Autophagy Apoptosis
Research Areas:
MPQPPAK is a polypeptide obtained from the enzymatic hydrolysis of C-phycocyanin (HY-D1025) and possesses neuroprotective activity. MPQPPAK enhances the activities of antioxidant enzymes SOD, CAT, and GSH-Px, reduces ROS, inhibits apoptosis and acetylcholinesterase (AChE) activity in brain tissue, and decreases protein carbonyl content. In the MPTP (HY-W114750)-induced zebrafish Parkinson's disease model, MPQPPAK exhibits antioxidant effects, inhibits autophagy and apoptosis, reverses the loss of dopaminergic neurons and cerebral blood vessels, and alleviates motor deficits. MPQPPAK can be used for research on Parkinson's disease .
Cat. No.: HY-P12337
Target:
Drug Derivative Cholinesterase (ChE) Reactive Oxygen Species (ROS) Caspase Keap1-Nrf2 PINK1/Parkin Bcl-2 Family Autophagy Apoptosis
Research Areas:
MTAAAR is a polypeptide obtained from the enzymatic hydrolysis of C-phycocyanin (HY-D1025) and possesses neuroprotective activity. MTAAAR enhances the activities of antioxidant enzymes SOD, CAT, and GSH-Px, reduces ROS, inhibits apoptosis and acetylcholinesterase (AChE) activity in brain tissue, and decreases protein carbonyl content. In the MPTP (HY-W114750)-induced zebrafish Parkinson's disease model, MTAAAR exhibits antioxidant effects, inhibits autophagy and apoptosis, reverses the loss of dopaminergic neurons and cerebral blood vessels, and alleviates motor deficits. MTAAAR can be used for research on Parkinson's disease .
Cat. No.: HY-100852R
CAS No.: 792957-74-5
Research Areas:
ER-000444793 (Standard) is the analytical standard of ER-000444793 (HY-100852). This product is intended for research and analytical applications. ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
Cat. No.: HY-186179
CAS No.: 37491-98-8
Category:
Target:
Cat. No.: HY-168169
Target:
Research Areas:
hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 of 424.1 nM and 177.9 nM, respectively. hMAO-B-IN-10 exerts a certain neuroprotective effect in MPTP (HY-15608)-induced mouse PD model. .
Cat. No.: HY-179417
Target:
Research Areas:
CypD-IN-7 is a potent cyclophilin D (CypD/PPIF) inhibitor that inhibits CypD PPIase activity (K i = 2.4 nM) and provides protection against mitochondrial permeability transition pore (MPTP) opening. CypD-IN-7 can be used for pancreatitis research .
Cat. No.: HY-179416
Target:
Research Areas:
CypD-IN-6 is a potent cyclophilin D (CypD/PPIF) inhibitor that inhibits CypD PPIase activity (Ki = 32 nM) and binds to CypD (Kd = 60 nM). CypD-IN-6 can be used for mitochondrial permeability transition pore (MPTP) related disease research such as ischemia-reperfusion injury and acute pancreatitis 1.
Cat. No.: HY-120206A
CAS No.: 173830-14-3
Synonyms: BMS-204756 maleate
Target:
Research Areas:
Brasofensine maleate(BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .
Cat. No.: HY-W223348
CAS No.: 759424-59-4
Research Areas:
Org-9768 (Compound (2-methyl-2,3-dihydro-1H-inden-2-yl)methanamine) is a drug intermediate for synthesizing the mitochondrial permeability transition pore (mPTP) inhibitor. Org-9768 can be used for the researches of neurological and cardiovascular disease, such as Parkinson's disease .
Cat. No.: HY-W839206
CAS No.: 3737-39-1
Target:
Research Areas:
NOS-IN-4 (Compound 3) is a neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 4.00 μM that inhibits nNOS activity. The combined use of alpha-lipoic acid and NOS-IN-4 has a protective effect against MPTP (HY-W114750)-induced dopamine depletion in the mouse brain. NOS-IN-4 can be used for the research of neurological disease .
Cat. No.: HY-W008719R
CAS No.: 36913-39-0
Research Areas:
MPP+ iodide (Standard) is the analytical standard of MPP+ iodide (HY-W008719). This product is intended for research and analytical applications. MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of ParKinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
Cat. No.: HY-184381
Target:
Research Areas:
MAO-B-IN-61 is an orally active, brain-penetrant, highly selective, mixed-type reversible MAO-B inhibitor (IC50 = 14 nM, SI for MAO-A > 2857). MAO-B-IN-61 exhibits no significant cytotoxicity across various human cell lines and demonstrates good metabolic stability in rat and human liver microsomes. In an MPTP (HY-W114750)-induced rat model of Parkinson's disease, MAO-B-IN-61 exhibits significantly improving motor function and positioning itself as a promising candidate for Parkinson's disease research .
Cat. No.: HY-187430
CAS No.: 2977213-17-3
Research Areas:
Dopamine D2 receptor agonist-4 is a blood-brain barrier permeable Dopamine D2 receptor agonist with an EC50 value of 0.03 nM. Dopamine D2 receptor agonist-4 reduces intracellular cAMP levels. Dopamine D2 receptor agonist-4 acts as a Ferroptosis inhibitor and iron chelator, selectively chelating iron ions, reducing intracellular ferrous ion levels, and exerting cytoprotective effects against iron-dependent ferroptosis in vitro. Dopamine D2 receptor agonist-4 improves motor dysfunction and exerts neuroprotective effects in mouse models of Parkinson's disease. Dopamine D2 receptor agonist-4 can be used in studies related to Parkinson's disease .
Cat. No.: HY-183665
CAS No.: 76778-24-0
Target:
Research Areas:
GBR-13119 is a blood-brain barrier-permeable inhibitor of the presynaptic dopamine uptake system. GBR-13119 binds to dopamine uptake sites with high selectivity, without being affected by other neurotransmitter reuptake inhibitors. GBR-13119 exhibits a lipophilic systemic distribution profile with extremely low defluorination in rats, while it shows a differential characteristic of slow striatal washout in the brain of primates. GBR-13119 can serve as a PET tracer to achieve visualized imaging of the striatum in primates, and can reflect MPTP-induced dopaminergic neuron degeneration through reduced uptake. GBR-13119 can be widely applied to studies related to Parkinson's disease and dopaminergic neuron degeneration .
Cat. No.: HY-15763R
CAS No.: 571203-78-6
Research Areas:
Erastin (Standard) is the analytical standard of Erastin (HY-15763). This product is intended for research and analytical applications. Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
Cat. No.: HY-179713
CAS No.: 3028684-07-0
Target:
Research Areas:
D2R/D3R/5-HT1AR agonist 1 (compound 22b) is an orally active triple-target D2R/D3R/5-HT1AR agonist with EC50 values of 1.29, 1.05 and 153.5 nM. D2R/D3R/5-HT1AR agonist 1 can improve the behavioral disorders induced by MPTP (HY-W114750) and exerts anti-depression effect. D2R/D3R/5-HT1AR agonist 1 can be used for the research of Parkinson's disease and depression .
Cat. No.: HY-184651
CAS No.: 3055155-53-5
Research Areas:
NLRP3-IN-93 is an orally active, blood-brain barrier-permeable NLRP3 inhibitor. NLRP3-IN-93 binds to the NACHT domain, blocks inflammasome assembly, and inhibits downstream IL-1β release, without significantly inhibiting various CYP isoforms. NLRP3-IN-93 demonstrates dose-dependent efficacy in mouse models of acute inflammation and Parkinson's disease, and exhibits good tolerability and an acceptable safety window in rats and dogs. NLRP3-IN-93 can be used in research on Parkinson's disease .
Cat. No.: HY-18542
CAS No.: 1402612-58-1
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
KT195 is a serine hydrolase inhibitor that targets ABHD6 (IC50 = 10 nM) and ABHD2, with no significant activity against DAGLβ. KT195 inhibits endoplasmic reticulum calcium release and mitochondrial calcium uptake by targeting ABHD2, thereby blocking A23187 (HY-N6687) and H2O2-induced necrotic cell death and apoptosis. By inhibiting ABHD6 activity, KT195 significantly induces 2-AG accumulation in Neuro2A cells and reduces IL-1β secretion in lipopolysaccharide-treated macrophages. KT195 has been used as a negative control probe for DAGLβ and can be applied in studies of ABHD6 and ABHD2 in calcium signaling, lipid metabolism, neuronal function, and inflammatory .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
